Be Bio's $82 million round announced Tuesday will help the Cambridge, MA-based biotech fund work for two of its drugs in ...

AvenCell Therapeutics on Tuesday said it collected $112 million to continue clinical studies of two experimental acute ...

AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech seeks clinical proof ...

Be Biopharma, Inc. ("Be Bio" or "the Company"), a leader in the discovery and development of engineered B Cell Medicines (BCMs), today announced key milestones alongside a new round of funding as its ...

Immunotherapies that mobilize a patient's own immune system to fight cancer have become a treatment pillar. These therapies, ...